Operator note

Do not delegate AI strategy to the product roadmap

May 2026.7 min read

Audience: CEOs of B2B software companies who currently chair an AI steering committee and review the AI roadmap monthly.

A CEO who delegates AI strategy to the CPO has chosen the smallest version of the AI question. Product roadmaps optimize inside the existing business model. The AI question is about the business model itself. The two look like the same conversation in a board paper. They are not. One produces a roadmap. The other produces a repricing, a margin reset, and a redesign of where the company captures value. A roadmap, however well-run, cannot do that work. This piece is about what stays on the CEO’s desk, what can be delegated, and what is lost when the delegation goes wrong.

The operating tension

Most CEOs in B2B software know the AI question matters. The pressure to show progress is also acute. The two pressures combine into a default move that looks reasonable from outside: appoint the CPO as the AI executive sponsor, fund an AI steering committee, review the AI roadmap monthly. The CEO retains oversight. The CPO carries the operational load. Everyone signals seriousness.

The trouble is that the operational load is in the wrong place. The decisions that move the second growth curve are not roadmap decisions. They are pricing, gross margin, go-to-market, and capital allocation decisions. The CPO has limited authority over any of those. The roadmap can ship, the demos can land, and the operating model can stay first-curve.

The false diagnosis

The first-time CEO reading of this is that the structure is wrong because the CPO is the wrong person. It is not. The CPO is usually the right person to run an AI product programme. The error is that running an AI product programme is being treated as running an AI strategy. Those are different jobs. The first is delegable. The second is not.

Why the delegation fails. Three reasons

One. Roadmaps optimise inside the existing business model. A product roadmap, by construction, takes the current pricing model, the current gross margin assumption, the current go-to-market motion, and the current capital allocation as fixed inputs. Within those constraints, it optimises features. AI changes the inputs, not the outputs. Per-seat pricing collapsed from 21 percent of SaaS to 15 in the twelve months to early 2026, and 83 percent of AI-native SaaS now bills on usage rather than seats (Monetizely, 2026; Stormy AI, 2026). A roadmap inside a seat-priced book cannot move that line.

Two. The cost line is not on the product owner’s authority. ICONIQ data puts the average AI product gross margin at 52 percent against the SaaS benchmark of 80, with inference at 23 percent of revenue at scaling-stage AI B2B companies (Monetizely, 2026). The decision about whether the company underwrites that 28-point margin reset, the pace at which it does so, and how it offsets the compression with pricing and repackaging is a CEO decision sitting on the CFO’s spreadsheet. It cannot be delegated to a product roadmap review.

Three. The go-to-market motion has to change in parallel. Median committees for deals above 50,000 dollars now sit at 11.2 stakeholders, the SaaS win rate median is at 22 percent, and procurement load adds two to four weeks to enterprise cycles (Corporate Visions, 2026; Martal, 2026). Rebuilding sales compensation, success motion, and forecasting around outcomes per account rather than seats per account is not a product decision. It is a commercial-model decision that lives with the CEO, the CRO, and the CFO together.

The pattern of what gets lost

When the delegation goes wrong, the same losses show up.

Pricing decisions sit. The product team is shipping AI capability. The pricing team is waiting for the product team to declare the capability ready. The product team is waiting for the pricing team to signal what the market will pay. Both wait for the CEO to break the dependency. Most CEOs do not, because the AI roadmap review has not surfaced pricing as a decision point. Months later, the renewal cohort prices itself for the company, downward.

Margin assumptions stay anchored to 80 points. The board pack continues to report against a SaaS gross margin benchmark that no longer applies. The first time the AI revenue line is large enough to dent the consolidated number, it shows up as a margin miss that nobody owns. The disclosure is the moment the strategy becomes visible to the market. The board hears about it the same week.

The go-to-market motion lags the product. Reps are still leading with seat counts on products that have shifted to usage in the backend. The success team is measuring adoption by login frequency on workflows the AI now completes without a login. Renewal calls expose the gap. The forecast misses by a quarter, and the diagnosis becomes “sales execution” rather than “go-to-market motion.”

The capital concentration never happens. The AI budget is distributed across the feature backlog because no executive other than the CEO has the authority to concentrate it. The company runs five AI programmes at one-fifth the effort. McKinsey reports 5.8x average ROI on production AI within 14 months, but only 29 percent of executives see significant returns (McKinsey, 2025; Writer, 2026). The 50-point gap between the average and the typical case is mostly the cost of running five distributed AI programmes instead of one concentrated one.

What stays on the CEO’s desk

Four decisions. None delegable.

One. Pricing model strategy. The choice of seat, usage, outcome, or hybrid, the sequencing of repricing across the product portfolio, and the renewal cohort to test first. This is not a pricing committee decision. It is a CEO decision informed by a pricing committee.

Two. AI-adjusted gross margin target and the disclosure plan. The choice of the new gross margin operating range, the timeline to disclose it externally, and the offsetting levers (pricing, packaging, support model, infrastructure). This is a CEO and CFO decision.

Three. Go-to-market motion redesign. The shift from access-based expansion to outcome-based expansion, the new comp plan, the new success metrics, and the new forecast model. This is a CEO, CRO, and CFO decision together.

Four. Capital concentration. The single workflow-collapse bet that gets 20 to 30 percent of the marginal AI budget. The CPO can identify candidates. The CEO has to pick.

What is delegable

Three decisions. All delegable.

One. The AI feature roadmap inside a chosen pricing model. Once the pricing model is set, the CPO can run the roadmap.

Two. The model-selection and infrastructure choices. Inference partner, hosting model, latency targets, observability stack. The CTO can run these inside the gross margin and inference-budget envelope set by the CEO and CFO.

Three. Customer evidence and case studies. The marketing and customer success leaders can run the proof points inside the brand and positioning guardrails.

The intervention

The change is structural. Replace the standing AI roadmap review with an AI economics review. Four numbers monthly: AI-adjusted gross margin, inference cost as a percent of AI revenue, pricing exposure at next renewal, outcome-priced share of new ARR. The AI roadmap continues, owned by the CPO, but it is no longer the strategic forum. The CEO chairs the AI economics review. The CPO presents into it.

The reorientation is small in form and large in consequence.

Roadmap reviews optimise inside the business model. Economics reviews change the business model.

The strategy lives in the second forum.

The leadership implication

Delegating AI strategy to the product roadmap is the most common version of AI roadmap theatre. It is also the most defensible-sounding, because the structure looks rational from the outside. The cost is hidden until renewal. The fix is to keep four decisions on the CEO’s desk, delegate three to the right operators, and replace the AI roadmap review with an AI economics review.

The rule of thumb

If the CEO can name the company’s AI feature roadmap but cannot name the company’s AI-adjusted gross margin, the inference cost as a percent of AI revenue, the pricing exposure at next renewal, and the outcome-priced share of new ARR, the AI strategy has been delegated to the wrong forum.

Sources

CEO, CPO, AI strategy, pricing, operating-model

Back to writing